肽類癌症疫苗市場：依研發階段、應用和地區分類

Peptide Cancer Vaccine Market, By Pipeline Phase, By Application, By Geography

出版日期: 2026年07月24日 | 出版商:

Coherent Market Insights | 英文 259 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，胜肽類癌症疫苗市場規模將達18億美元，到2033年將達82億美元。預計從2026年到2033年，其複合年成長率將達到24.3%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	18億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	24.30%	2033年市場規模預測：	82億美元

該市場正經歷著顯著的變革，其主要驅動力在於個人化癌症免疫療法的日益普及、對標靶治療方案需求的成長以及對腫瘤免疫反應解決方案的日益關注。肽類癌症疫苗，包括個人化疫苗、共用抗原疫苗和多胜肽疫苗，能夠使免疫系統有效辨識腫瘤抗原，同時應對腫瘤異質性、免疫逃脫和安全性問題。該市場涵蓋廣泛的產品應用，例如惡性黑色素瘤、肺癌、乳癌、前列腺癌、胃腸道癌症、骨髓惡性腫瘤和固體癌的治療。

患者和醫療專業人員正致力於精準激活免疫反應和採用治療方法，以改善治療效果、控制腫瘤並維持患者的生活品質。新抗原鑑定、胜肽合成和佐劑遞送技術的進步正在提升疫苗的性能，尤其是在治療抗藥性或復發性癌症患者中。此外，基因測序和聯合免疫療法的廣泛應用，使得患者篩選和免疫反應最佳化成為可能，從而改善臨床療效並減輕癌症治療的負擔。

市場動態

由於癌症發生率上升、腫瘤特異性免疫療法投資增加以及對能夠誘導持續免疫反應的療法的需求不斷成長，市場呈現出強勁的成長動能。市場成長的主要驅動力來自生技公司和研究機構，他們致力於開發精準、適應性強且安全的治療性疫苗平台，尤其針對黑色素瘤、膠質母細胞瘤、前列腺癌、卵巢癌、胰腺癌以及其他需要靶向免疫干預的惡性腫瘤。腫瘤相關抗原、合成胜肽、免疫佐劑和抗原呈現細胞技術在疫苗研發中發揮核心作用，有助於活化細胞毒性T細胞、提高腫瘤辨識能力並抑制疾病進展。對個人化醫療、復發預防和基於免疫療法的腫瘤學的日益重視，正在推動對肽類癌症疫苗的需求成長。

新抗原發現計畫的拓展正在推動市場成長。這主要得益於基因組分析技術的日益普及、先進胜肽合成平台的出現以及基於腫瘤突變設計的生物標記驅動型疫苗的廣泛應用。查核點抑制劑、化療和免疫促效劑的聯合療法有助於提高治療反應率並克服腫瘤誘導的免疫抑制。

對毒性較小的癌症療法的需求日益成長，也推動了市場的發展。腫瘤內科醫生、免疫學家、臨床研究人員、藥物研發人員、診斷實驗室和專科癌症中心在胜肽疫苗候選藥物的評估和開發中發揮著至關重要的作用。隨著對腫瘤免疫學認知的不斷加深，市場有望受益於臨床開發的進步、患者篩選準確性的提高以及更個性化、更有效且擴充性的癌症疫苗解決方案的推出。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了胜肽類癌症疫苗市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份「胜肽類癌症疫苗市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析肽類癌症疫苗市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Marker Therapeutics, Inc.
- Agenus
- Merck
- BrightPath Biotherapeutics
- Boston Biomedical
- VAXON Biotech
- Nouscom
- Lytix Biopharma
- ISA Pharmaceuticals
- Generex Biotechnology
- OncoTherapy Science
- Enzo Life Science
- Immatics Biotechnologies
- SELLAS Life Sciences Group
- Ultimovacs
- Celldex therapeutics
- Immunomic Therapeutics, Inc.
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI1634

Peptide Cancer Vaccine Market is estimated to be valued at USD 1.8 Bn in 2026 and is expected to reach USD 8.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 24.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.8 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	24.30%	2033 Value Projection:	USD 8.2 Bn

The market is undergoing a major transformation mainly driven by rising adoption of personalized cancer immunotherapies, increasing demand for targeted treatment options, and growing emphasis on antitumor immune response solutions. Peptide cancer vaccines, including personalized, shared-antigen, and multipeptide formulations, enable immunity to recognize tumor antigens efficiently while addressing tumor heterogeneity, immune escape, and safety standards. The market includes a wide array of product applications like melanoma, lung cancer, breast cancer, prostate cancer, gastrointestinal cancers, hematological malignancies, and solid tumor treatment.

Patients and healthcare providers are focusing on precise immune activation and therapeutic approaches to enhance treatment outcomes, ensure tumor control, and maintain quality of life. The advancements in neoantigen identification, peptide synthesis, and adjuvant delivery tools are improving vaccine performance, especially in patients with treatment-resistant or recurrent cancers. In addition, the growing use of genomic sequencing and combination immunotherapy regimens helps optimize patient selection and immune response, thereby improving clinical outcomes and reducing burden of cancer treatment.

Market Dynamics

The market is witnessing major momentum owing to increasing prevalence of cancer, rising investment in tumor-specific immunotherapy, and the growing need for treatments capable of generating durable immune responses. The market's growth is largely driven by biotechnology companies and research institutions seeking precise, adaptable, and safe therapeutic vaccine platforms, especially for melanoma, glioblastoma, prostate cancer, ovarian cancer, pancreatic cancer, and other malignancies requiring targeted immune intervention. Tumor-associated antigens, synthetic peptides, immune adjuvants, and antigen-presenting cell technologies play a central role in vaccine development, thereby helping activate cytotoxic T cells, improve tumor recognition, and limit disease progression. The rising focus on individualized treatment, recurrence prevention, and immune-based oncology is strengthening the demand for peptide cancer vaccines.

The expansion of neoantigen discovery programs is fueling market growth. This is mainly driven by increasing adoption of genomic profiling, availability of advanced peptide synthesis platforms, and biomarker-guided vaccines designed according to tumor mutations. Combination approaches involving checkpoint inhibitors, chemotherapy, and immune-stimulating agents help improve response rates and overcome tumor-induced immune suppression.

The rising demand for less toxic cancer therapies is also propelling the market. Oncologists, immunologists, clinical researchers, pharmaceutical developers, diagnostic laboratories, and specialized cancer centers play a crucial role in evaluating and advancing peptide vaccine candidates. As understanding of tumor immunology grows, the market is expected to benefit from clinical development, improved patient selection, and the introduction of more personalized, effective, and scalable cancer vaccination solutions.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Peptide Cancer Vaccine Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Marker Therapeutics, Inc., Agenus, Merck, BrightPath Biotherapeutics, Boston Biomedical, VAXON Biotech, Nouscom, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Immatics Biotechnologies, SELLAS Life Sciences Group, Ultimovacs, Celldex therapeutics, Immunomic Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Peptide Cancer Vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Peptide Cancer Vaccine Market

Market Segmentation

By Pipeline Phase (Revenue, USD Bn, 2021-2033)
Research
Preclinical
Phase-I
Phase-I/II
Phase-II
Phase-III
By Application (Revenue, USD Bn, 2021-2033)
Colorectal Cancer
Lung Cancer
Pancreatic Cancer
Gastric Cancer
Prostate Cancer
Breast Cancer
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players Insights
Marker Therapeutics, Inc.
Agenus
Merck
BrightPath Biotherapeutics
Boston Biomedical
VAXON Biotech
Nouscom
Lytix Biopharma
ISA Pharmaceuticals
Generex Biotechnology
OncoTherapy Science
Enzo Life Science
Immatics Biotechnologies
SELLAS Life Sciences Group
Ultimovacs
Celldex therapeutics
Immunomic Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Pipeline Phase
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Disease Type Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Peptide Cancer Vaccine Market, By Pipeline Phase, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Phase-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Phase-I/II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Phase-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Phase-III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Peptide Cancer Vaccine Market, By Application, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Gastric Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Peptide Cancer Vaccine Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Marker Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Agenus
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Merck
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- BrightPath Biotherapeutics
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Boston Biomedical
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- VAXON Biotech
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Nouscom
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Lytix Biopharma
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- ISA Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Generex Biotechnology
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- OncoTherapy Science
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Enzo Life Science
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Immatics Biotechnologies
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- SELLAS Life Sciences Group
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Ultimovacs
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Celldex therapeutics
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Immunomic Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views